NSG 5240 - Advanced Pharmacology
Midterm Exam Questions and Verified Answers
with Rationale Latest Edition 2026/2027
Question 1
What is the primary mechanism of action of beta-1 adrenergic
antagonists (beta-blockers) in the treatment of heart failure?
A. They competitively block catecholamine binding to beta-1
receptors, decreasing heart rate, myocardial contractility, and renin
release to reduce cardiac workload and remodeling.
B. They directly stimulate peripheral vasodilation by activating
smooth muscle potassium channels.
C. They inhibit the degradation of cyclic AMP, causing a positive
inotropic effect.
D. They block angiotensin-converting enzyme to lower systemic
vascular resistance.
Correct Answer:
A
Rationale:
Beta-blockers reduce sympathetic nervous system overdrive in heart
failure by blocking beta-1 receptors in the heart and juxtaglomerular
apparatus, lowering myocardial oxygen demand, heart rate, and
pathologic remodeling.
Question 2
,Which pharmacokinetic parameter determines the time required for a
drug's plasma concentration to decrease by half, and how many half-
lives does it typically take to reach steady-state plasma concentrations?
A. Half-life; approximately 4 to 5 half-lives.
B. Clearance; exactly 2 half-lives.
C. Volume of distribution; 10 half-lives.
D. Bioavailability; a single half-life.
Correct Answer:
A
Rationale:
The half-life dictates elimination rate. Following repeated fixed-dose
administration, a drug reaches steady-state concentrations after
approximately 4 to 5 half-lives, when the rate of drug elimination equals
the rate of drug administration.
Question 3
Why are ACE inhibitors considered first-line pharmacotherapy in
patients with diabetes mellitus and early diabetic nephropathy?
A. They dilate the efferent renal arteriole more than the afferent
arteriole, lowering intraglomerular pressure and reducing
proteinuria and progressive glomerular damage.
B. They directly stimulate insulin synthesis and secretion from
pancreatic beta cells.
C. They prevent urinary tract infections by acidifying the urine.
D. They block sodium-glucose cotransporters in the proximal
convoluted tubule.
Correct Answer:
A
,Rationale:
ACE inhibitors preferentially dilate the efferent arteriole of the
glomerulus, reducing glomerular hydraulic pressure and slowing the
progression of diabetic nephropathy independent of their systemic blood
pressure-lowering effects.
Question 4
Which laboratory parameter must be closely monitored when initiating
therapy with spironolactone in a patient with heart failure?
A. Serum potassium and renal function (blood urea nitrogen and
serum creatinine).
B. Complete blood count and differential leukocyte levels.
C. Fasting blood glucose and glycated hemoglobin.
D. Serum thyroid-stimulating hormone and free thyroxine.
Correct Answer:
A
Rationale:
Spironolactone is a potassium-sparing diuretic and aldosterone receptor
antagonist that can cause hyperkalemia and acute kidney injury,
particularly when combined with ACE inhibitors or angiotensin receptor
blockers.
Question 5
What is the primary pharmacological difference between selective beta-
1 blockers (cardioselective) and non-selective beta-blockers?
A. Cardioselective agents (e.g., metoprolol, atenolol) primarily
target cardiac beta-1 receptors at lower doses, whereas non-
, selective agents (e.g., propranolol) block both beta-1 and beta-2
receptors, risking bronchospasm.
B. Non-selective blockers have zero effect on heart rate but lower
blood pressure exclusively.
C. Cardioselective agents stimulate alpha-1 receptors
simultaneously.
D. Non-selective agents are entirely metabolized by the kidneys
without hepatic involvement.
Correct Answer:
A
Rationale:
Selectivity minimizes unwanted side effects such as bronchoconstriction
mediated by beta-2 receptor blockade in the lungs, making
cardioselective agents safer for patients with mild reactive airway
disease.
Question 6
What is the mechanism of action of direct oral anticoagulants (DOACs)
such as apixaban or rivaroxaban?
A. They act as direct, selective inhibitors of factor Xa, preventing
the conversion of prothrombin to thrombin.
B. They potentiate antithrombin III to inhibit thrombin and factor
IXa.
C. They irreversibly inhibit cyclooxygenase-1 in platelets.
D. They directly lyse existing fibrin clots by activating
plasminogen.
Correct Answer:
A
Midterm Exam Questions and Verified Answers
with Rationale Latest Edition 2026/2027
Question 1
What is the primary mechanism of action of beta-1 adrenergic
antagonists (beta-blockers) in the treatment of heart failure?
A. They competitively block catecholamine binding to beta-1
receptors, decreasing heart rate, myocardial contractility, and renin
release to reduce cardiac workload and remodeling.
B. They directly stimulate peripheral vasodilation by activating
smooth muscle potassium channels.
C. They inhibit the degradation of cyclic AMP, causing a positive
inotropic effect.
D. They block angiotensin-converting enzyme to lower systemic
vascular resistance.
Correct Answer:
A
Rationale:
Beta-blockers reduce sympathetic nervous system overdrive in heart
failure by blocking beta-1 receptors in the heart and juxtaglomerular
apparatus, lowering myocardial oxygen demand, heart rate, and
pathologic remodeling.
Question 2
,Which pharmacokinetic parameter determines the time required for a
drug's plasma concentration to decrease by half, and how many half-
lives does it typically take to reach steady-state plasma concentrations?
A. Half-life; approximately 4 to 5 half-lives.
B. Clearance; exactly 2 half-lives.
C. Volume of distribution; 10 half-lives.
D. Bioavailability; a single half-life.
Correct Answer:
A
Rationale:
The half-life dictates elimination rate. Following repeated fixed-dose
administration, a drug reaches steady-state concentrations after
approximately 4 to 5 half-lives, when the rate of drug elimination equals
the rate of drug administration.
Question 3
Why are ACE inhibitors considered first-line pharmacotherapy in
patients with diabetes mellitus and early diabetic nephropathy?
A. They dilate the efferent renal arteriole more than the afferent
arteriole, lowering intraglomerular pressure and reducing
proteinuria and progressive glomerular damage.
B. They directly stimulate insulin synthesis and secretion from
pancreatic beta cells.
C. They prevent urinary tract infections by acidifying the urine.
D. They block sodium-glucose cotransporters in the proximal
convoluted tubule.
Correct Answer:
A
,Rationale:
ACE inhibitors preferentially dilate the efferent arteriole of the
glomerulus, reducing glomerular hydraulic pressure and slowing the
progression of diabetic nephropathy independent of their systemic blood
pressure-lowering effects.
Question 4
Which laboratory parameter must be closely monitored when initiating
therapy with spironolactone in a patient with heart failure?
A. Serum potassium and renal function (blood urea nitrogen and
serum creatinine).
B. Complete blood count and differential leukocyte levels.
C. Fasting blood glucose and glycated hemoglobin.
D. Serum thyroid-stimulating hormone and free thyroxine.
Correct Answer:
A
Rationale:
Spironolactone is a potassium-sparing diuretic and aldosterone receptor
antagonist that can cause hyperkalemia and acute kidney injury,
particularly when combined with ACE inhibitors or angiotensin receptor
blockers.
Question 5
What is the primary pharmacological difference between selective beta-
1 blockers (cardioselective) and non-selective beta-blockers?
A. Cardioselective agents (e.g., metoprolol, atenolol) primarily
target cardiac beta-1 receptors at lower doses, whereas non-
, selective agents (e.g., propranolol) block both beta-1 and beta-2
receptors, risking bronchospasm.
B. Non-selective blockers have zero effect on heart rate but lower
blood pressure exclusively.
C. Cardioselective agents stimulate alpha-1 receptors
simultaneously.
D. Non-selective agents are entirely metabolized by the kidneys
without hepatic involvement.
Correct Answer:
A
Rationale:
Selectivity minimizes unwanted side effects such as bronchoconstriction
mediated by beta-2 receptor blockade in the lungs, making
cardioselective agents safer for patients with mild reactive airway
disease.
Question 6
What is the mechanism of action of direct oral anticoagulants (DOACs)
such as apixaban or rivaroxaban?
A. They act as direct, selective inhibitors of factor Xa, preventing
the conversion of prothrombin to thrombin.
B. They potentiate antithrombin III to inhibit thrombin and factor
IXa.
C. They irreversibly inhibit cyclooxygenase-1 in platelets.
D. They directly lyse existing fibrin clots by activating
plasminogen.
Correct Answer:
A
